Compare Hecla Mining Company Common Stock (HL) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hecla Mining Company Common Stock vs Spyre Therapeutics Inc. Common Stock — how do they compare? Hecla Mining Company Common Stock trades at $15.03 (market cap $10.87B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: Hecla Mining Company Common Stock is the larger of the two by market cap, and Hecla Mining Company Common Stock pays a 0.09% dividend while Spyre Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Hecla Mining Company Common Stock for 3 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| HL | SYRE | |
|---|---|---|
Market Cap | $10.87B | $7.52B |
Volume | 31,516,848 | 1,441,031 |
Sector | Basic Materials | Health |
52-Week High | $31.81 | $108.92 |
52-Week Low | $11.97 | $22.18 |
Typical Hold Time | 3 Days | 0 Days |
Enterprise Value | $10.40B | $6.52B |
Dividend Yield | 0.09% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hecla Mining (HL) trades at $16.18, down 3.92% on the day, amid a bearish technical signal. The stock shows strong fundamentals with a 51.68% gross margin and 19.15% net income margin, but recent quarterly earnings missed expectations. Positive news highlights a debt-free balance sheet and organic growth targeting over 20 million silver ounces, while institutional activity includes new investments from Bank of America and AlphaGrep.
The outlook is mixed: analyst consensus is a Buy with a $23.44 price target, implying 45% upside, but technical indicators signal near-term pressure. Key risks include silver price volatility and execution of growth projects. The stock presents a value opportunity for long-term investors if operational targets are met.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Hecla Mining Company Common Stock
Hecla Mining is a precious metals producer focused on silver and gold. It operates mines in the United States and Canada.
Read more on HL →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
